NPHLA Daily
NPHLA Daily
Monday, November 2, 2026 · 4-minute read
Good morning. Here is what changed across metabolic medicine, pharmacy regulation, aesthetics and healthcare technology since yesterday — every item linked to its source.
Top development today
What changed today in Regulatory: 1 new study
NPHLA tracked 1 new official record on this desk today: 1 new study. First: New research in JAAD case reports: “Pigmented purpura dermatosis associated with compounded semaglutide: A case report and literature review of medication-associated pigmented purpuric dermatosis”.
Metabolic signal
What changed today in Metabolic: 1 new study
NPHLA tracked 1 new official record on this desk today: 1 new study. First: New research in Molecular metabolism: “Differentiated obesity treatment: Pharmacological CRF2 agonism drives fat loss, skeletal muscle hypertrophy and improved glucose metabolism in preclinical obesity”.
Regulatory signal
Pigmented purpura dermatosis associated with compounded semaglutide: A case report and literature review of medication-associated pigmented purpuric dermatosis
From JAAD case reports.
One thing worth watching
Comments close: Compounding Animal Drugs From Bulk Drug Substances: Compounding Under CGMP in Federally-Registered Facilities; Draft Guidance for Industry; Availability; Agency Information…
November 26, 2026 — verified from the Federal Register comments_close_on.
5 things to know
- What changed today in Regulatory: 1 new study
- What changed today in Metabolic: 1 new study
- Pigmented purpura dermatosis associated with compounded semaglutide: A case report and literature review of medication-associated pigmented purpuric dermatosis (JAAD case reports)
- Compounding Through Crisis: Developing Safe Processes During Drug Shortages (International journal of pharmaceutical compounding)
- Hospital Compounding: More Than a Pharmacy Issue (International journal of pharmaceutical compounding)
Compiled by NPHLA Intelligence from published briefings and official records. Professional information only — not medical or legal advice. Our standards.